Dr. Michael Kazim, MD

Dr. Kazim practices at New York Eye and Ear Infirmary of Mount Sinai in New York, New York, part of Mount Sinai Health System.

Dr. Kazim's NPI, 1265452213, was assigned on July 20, 2006. Dr. Kazim graduated from Columbia University College of Physicians and Surgeons in 1984. Dr. Kazim holds New York license 162657-1.

Dr. Kazim's primary practice is New York Eye and Ear Infirmary of Mount Sinai, at 230 Second Ave, New York, NY 10003 in New York County. The practice phone is (212) 979-4000. Dr. Kazim also practices at New York Eye & Ear Infirmary, 310 E 14th St, New York, NY 10003.

Dr. Kazim's primary practice is New York Eye and Ear Infirmary of Mount Sinai in New York, New York, part of Mount Sinai Health System. Dr. Kazim is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. Dmand AI also links Dr. Kazim to 1 more hospital and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kazim practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Kazim's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Kazim is licensed in New York.

CMS data shows 457 Medicare services from Dr. Kazim across 8 procedure codes in 2024, for 311 Medicare patients. Medicare paid $38,724 for them. Every service was in an office.

CMS counts 311 Medicare patients who saw Dr. Kazim in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kazim's median patient age at 69, with 59% women.

In 2024, Dr. Kazim wrote 105 Medicare Part D claims for 64 patients. 64% of them were for generic drugs. CMS names the drug for 66 of them, across 3 drugs with 11 or more claims each, at $1,366 in total drug cost. In 2023, CMS named 77 claims across 3 drugs.

Dr. Kazim accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 126 papers to Dr. Kazim, published from 2011 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Graves Ophthalmopathy, Magnetic Resonance Imaging and Orbit. Dr. Kazim has published most often in Ophthalmic Plast Reconstr Surg. Dr. Kazim's most frequent co-authors are Andrea Tooley, Kyle J. Godfrey, MD and Kristen Elizabeth Dunbar, MD.

Dmand AI links Dr. Kazim to 1 clinical trial. Conditions studied include Graves Ophthalmopathy and Exophthalmos.

CMS Open Payments shows 8 general payments to Dr. Kazim from 3 drug and device companies from 2016 to 2025. Education make up the largest share, 67% of the total. Shire North American Group Inc paid the most, $226.

Dr. Kazim graduated from Columbia University College of Physicians and Surgeons in 1984.